06 Oct 2021 Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer Member news
04 Oct 2021 Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease Member news
04 Oct 2021 Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON) Member news
29 Sep 2021 Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC) Member news
09 Sep 2021 Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases Member news
03 Sep 2021 Novalis Biotech Acceleration invests in San Francisco-based Modality.AI - technology that ‘self-drives’ neurological and psychiatric assessments Member news
01 Sep 2021 ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 Member news
17 Aug 2021 Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science Member news
15 Jul 2021 Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study Member news
15 Jul 2021 Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
